Kyle Leeman
About Kyle Leeman
Kyle Leeman serves as the Vice President of Analytical Development and Quality Control at Mirati Therapeutics, bringing over 30 years of experience in analytical research and development within the pharmaceutical industry.
Work at Mirati Therapeutics
Kyle Leeman serves as the Vice President of Analytical Development and Quality Control at Mirati Therapeutics. He has held this position since 2021, contributing to the company's efforts in the pharmaceutical sector. In this role, he manages both internal and external Good Manufacturing Practice (GMP) and non-GMP analytical activities. His work supports the development of products from early stages through to commercial release, ensuring compliance with industry standards and regulatory requirements.
Previous Experience at Neurocrine Biosciences
Before joining Mirati Therapeutics, Kyle Leeman worked at Neurocrine Biosciences as the Executive Director of Analytical Development from 2017 to 2021. During his four years in this role, he was responsible for leading analytical development initiatives in the Greater San Diego Area. His experience at Neurocrine contributed to his extensive background in analytical research and development within the pharmaceutical industry.
Career at Pfizer
Kyle Leeman spent 27 years at Pfizer, where he held the position of Associate Research Fellow from 1990 to 2017. His long tenure at Pfizer allowed him to gain significant expertise in analytical research and development. This experience laid the foundation for his subsequent roles in the pharmaceutical industry, including his leadership positions at Neurocrine Biosciences and Mirati Therapeutics.
Education and Expertise
Kyle Leeman earned a Bachelor of Science degree in Chemistry from Quinnipiac University, completing his studies from 1986 to 1990. His educational background in chemistry provides a strong foundation for his extensive career in analytical research and development within the pharmaceutical industry. This expertise has been instrumental in his roles at various organizations, including Mirati Therapeutics, Neurocrine Biosciences, and Pfizer.